-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $29

Benzinga·03/18/2026 12:52:06
Listen to the news
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $30 to $29.